OTCMKTS:IPHYF - Innate Pharma Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $5.46 0.00 (0.00 %) (As of 07/20/2018 04:00 PM ET)Previous Close$5.46Today's Range$5.46 - $5.4652-Week Range$4.92 - $13.39VolumeN/AAverage Volume120 shsMarket Capitalization$314.50 millionP/E Ratio-5.41Dividend YieldN/ABeta1.24 Company ProfileAnalyst RatingsHeadlinesSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. It offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas; Monalizumab, a checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications, as well as in Phase I/II clinical trial for the treatment of solid tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. The company also provides Lirilumab (IPH2102/BMS-986015), a human monoclonal antibody that blocks the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands; IPH52, an anti-CD39 antibody for immuno-oncology; IPH53, an anti-CD73 antibody for immuno-oncology; and IPH4301, an anti-MICA/B therapeutic antibody to treat oncology. The company has licensing agreements with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi. Innate Pharma S.A. has a clinical trial collaboration with MedImmune. The company was founded in 1999 and is based in Marseille, France. Receive IPHYF News and Ratings via Email Sign-up to receive the latest news and ratings for IPHYF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolOTCMKTS:IPHYF CUSIPN/A Webwww.innate-pharma.com Phone33-04-30-30-30-30 Debt Debt-to-Equity RatioN/A Current Ratio1.86 Quick RatioN/A Price-To-Earnings Trailing P/E Ratio-5.41 Forward P/E Ratio-3.69 P/E GrowthN/A Sales & Book Value Annual Sales$49.74 million Price / Sales6.32 Cash FlowN/A Price / CashN/A Book Value$1.80 per share Price / Book3.03 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees154 Outstanding Shares57,600,000Market Cap$314.50 Innate Pharma (OTCMKTS:IPHYF) Frequently Asked Questions What is Innate Pharma's stock symbol? Innate Pharma trades on the OTCMKTS under the ticker symbol "IPHYF." What is the consensus analysts' recommendation for Innate Pharma? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Innate Pharma's key competitors? Some companies that are related to Innate Pharma include Eagle Pharmaceuticals (EGRX), Alder Biopharmaceuticals (ALDR), Retrophin (RTRX), Zai Lab (ZLAB), Reata Pharmaceuticals (RETA), Tricida (TCDA), Endocyte (ECYT), Athenex (ATNX), Esperion Therapeutics (ESPR), Intra-Cellular Therapies (ITCI), Wave Life Sciences (WVE), Vanda Pharmaceuticals (VNDA), Revance Therapeutics (RVNC), Apellis Pharmaceuticals (APLS) and Flexion Therapeutics (FLXN). Who are Innate Pharma's key executives? Innate Pharma's management team includes the folowing people: Dr. Hervé Brailly Ph.D., Co-Founder and Chairman of Supervisory Board (Age 56)Mr. Yannis Morel, Exec. VP-Products Portfolio Strategy & Bus. Devel. & Member of Exec. Board (Age 44)Mrs. Catherine Moukheibir MA, MBA, Advisor (Age 59)Dr. Mondher Mahjoubi M.D., Chairman of Exec. Board and Chief Exec. Officer (Age 59)Dr. François Romagné Ph.D., Co Founder and Member of the Scientific Advisory Board (Age 54) Has Innate Pharma been receiving favorable news coverage? Media coverage about IPHYF stock has been trending somewhat negative this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Innate Pharma earned a news sentiment score of -0.05 on Accern's scale. They also assigned news coverage about the company an impact score of 43.98 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days. How do I buy shares of Innate Pharma? Shares of IPHYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Innate Pharma's stock price today? One share of IPHYF stock can currently be purchased for approximately $5.46. How big of a company is Innate Pharma? Innate Pharma has a market capitalization of $314.50 million and generates $49.74 million in revenue each year. The company earns $-54,680,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Innate Pharma employs 154 workers across the globe. How can I contact Innate Pharma? Innate Pharma's mailing address is 117 Avenue de Luminy, Marseille I0, 13009. The company can be reached via phone at 33-04-30-30-30-30 or via email at [email protected] MarketBeat Community Rating for Innate Pharma (OTCMKTS IPHYF)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 52 (Vote Outperform)Underperform Votes: 38 (Vote Underperform)Total Votes: 90MarketBeat's community ratings are surveys of what our community members think about Innate Pharma and other stocks. Vote "Outperform" if you believe IPHYF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPHYF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/21/2018 by MarketBeat.com StaffFeatured Article: What do I need to know about analyst ratings?